Company Profile
Eton Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- ETON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
61.73 USD (+4.88%)
Close
Last updated: August 17, 2026
751M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ETON closed up 4.88% at $61.73. No new same-company headline was identified in the current news window.
Company overview
Rare Disease Commercialization Company
Eton Pharmaceuticals develops and commercializes treatments for rare diseases. Its portfolio includes ten commercial products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Expanding Commercial Portfolio
During 2026, Eton received FDA approval for and launched DESMODA, while also acquiring and relaunching HEMANGEOL. The Eton Cares support platform and rare-disease distribution model are intended to improve access and adherence.
Acquisition and Licensing Model
Eton builds its portfolio by acquiring or licensing products that can be commercialized through a focused rare-disease infrastructure. This allows the company to add approved products and late-stage candidates without relying solely on internally discovered assets.
Late-Stage Pipeline
The company has four late-stage candidates: Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. Additional work includes a KHINDIVI label expansion, extended-release zinc acetate candidate ET-700, and label harmonization for INCRELEX.
Rare Disease Patient Support
Eton Cares provides reimbursement assistance, product access, and adherence support across the portfolio. A shared patient-services infrastructure allows newly acquired products to be integrated into the company’s existing rare-disease commercial organization.
Future catalysts
- Commercial launch of IMPAVIDO in September 2026.
- Submission of an NDA for AMGLIDIA by the end of 2026.
- First-patient dosing in the INCRELEX label-harmonization study by the end of 2026.
- Potential FDA approval of the expanded KHINDIVI indication in the first half of 2027.
- Initiation of a pivotal study of ET-700 in early 2027, subject to supportive pilot results.
- Submission of an NDA for ASN-001 in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Eton Pharmaceuticals (ETON)?
Eton Pharmaceuticals (ETON) most recently closed at 61.73 USD, a +4.88% move versus the previous session.
What is the market cap of Eton Pharmaceuticals (ETON)?
Eton Pharmaceuticals currently has a market capitalization of 751M USD on BioPharmSignal.
What does Eton Pharmaceuticals do?
Rare Disease Commercialization Company Eton Pharmaceuticals develops and commercializes treatments for rare diseases. Its portfolio includes ten commercial products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. Expanding Commercial Portfolio During 2026, Eton received FDA...
On which exchange is ETON stock listed?
Eton Pharmaceuticals (ETON) is associated with NASDAQ, United States, Biopharma.
What is ET-700?
Initiation of a pivotal study of ET-700 in early 2027, subject to supportive pilot results.
Which conditions is Eton Pharmaceuticals targeting with ET-700?
Eton Pharmaceuticals is associated with rare disease based on its company overview and current catalyst commentary.
How does Eton Pharmaceuticals describe recent progress with ET-700?
Initiation of a pivotal study of ET-700 in early 2027, subject to supportive pilot results.
What is ET-800?
Late-Stage Pipeline The company has four late-stage candidates: Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector.